Application of simvastatin in preparation of medicine for preventing or treating liver cancer

A technology for treating liver cancer with simvastatin, which is applied in the field of medicine, can solve the problems that there is no simvastatin, and achieve the effects of increasing effectiveness and safety, promoting apoptosis of liver cancer cells, and ensuring safety

Pending Publication Date: 2022-03-15
诸暨市人民医院 +1
View PDF12 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, how to select a combination from a large number of drugs that can produce synergistic effects and reduce toxicity in the treatment of liver cancer when combined with immune checkpoint inhibitors has become a new challenge for scientists in the field of drug development
[0006] There are no studies on the use of simvastatin for the prevention or treatment of liver cancer or the combination of simvastatin and immune checkpoint inhibitors in the prevention or treatment of liver cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of simvastatin in preparation of medicine for preventing or treating liver cancer
  • Application of simvastatin in preparation of medicine for preventing or treating liver cancer
  • Application of simvastatin in preparation of medicine for preventing or treating liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] Example 1: Effect of simvastatin on human liver cancer cell HepG2 cultured in vitro

[0044] 1. Main experimental materials

[0045] The human hepatocellular carcinoma cell line HepG2 was purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences; the simvastatin standard product was purchased from MCE Company (purity above 99.5%); the CCK-8 staining solution was purchased from Beijing Biyuntian Technology Company; the Transwell chamber was purchased from the United States Corning Corporation; Bcl-2, Bax and β-Actin monoclonal antibodies and HRP-labeled secondary antibodies were purchased from Cell signalingTechnology, USA.

[0046] 2. Experimental method

[0047] 2.1 Culture of human liver cancer cell line HepG2

[0048] Human liver cancer cell line HepG2 was cultured in DMEM medium containing 10% fetal bovine serum, 1% penicillin and streptomycin at 37°C, 5% CO 2 In the incubator, the cells were subcultured when they reached a confluence of 90%, and u...

Embodiment 2

[0102] Embodiment 2: the influence of the medicine of the present invention on human hepatocellular carcinoma Hep3B mouse xenograft tumor model

[0103] 1. Experimental materials

[0104] 1.1 Animals

[0105] SPF grade BALB / c female nude mice, 6-8 weeks old, weighing 18-22 g, were purchased from Shanghai Experimental Animal Research Center.

[0106] 1.2 Main Drugs and Reagents

[0107] Human hepatocellular carcinoma cell line Hep3B was purchased from the Shanghai Cell Bank of the Chinese Academy of Sciences; simvastatin standard and fenofibrate standard were purchased from MCE (purity above 99.5%); atezolizumab injection (60mg / mL) was purchased from Roche.

[0108] 2. Experimental method

[0109] 2.1 Establishment and administration of transplanted tumor model

[0110] BALB / c female nude mice were raised at room temperature, and after they adapted to the environment, they were inoculated with Hep3B cells, and each nude mouse was injected with 6×10 7 cells. One week aft...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of medicines, and particularly relates to application of simvastatin in preparation of a medicine for preventing or treating liver cancer. Pharmacological experiment results show that simvastatin can inhibit proliferation, migration and invasion of liver cancer cells HepG2 and promote apoptosis of liver cancer cells. Furthermore, the medicament further comprises a second active ingredient, which is an immune checkpoint inhibitor. Pharmacological experiment results show that the medicine containing the second active component significantly inhibits the growth of transplanted tumors in nude mice with human liver cancer Hep3B, and the effect is significantly better than that of single use of simvastatin and immune checkpoint inhibitor in the same dose, which shows that after the medicine is combined, the medicine has significant synergistic interaction and good clinical application prospects.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of simvastatin in the preparation of drugs for preventing or treating liver cancer. The present invention also relates to the application of the combination of simvastatin and immune checkpoint inhibitors in the preparation of drugs for preventing or treating liver cancer. Background technique [0002] Hepatocellular carcinoma (hepatocellular carcinoma, HCC) ranks sixth in the incidence of malignant tumors in the world, and more than half of the new cases and deaths of liver cancer each year are in China. The latest statistics show that the incidence of liver cancer in my country ranks fourth among malignant tumors, and its case fatality rate ranks second among malignant tumors. At present, the traditional treatment of liver cancer mainly relies on surgical resection, as well as liver transplantation, thermal radiofrequency, and hepatic arterial chemoembolizat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61K45/06A61P35/00A61P1/16
CPCA61K31/366A61K45/06A61P35/00A61P1/16A61K2300/00
Inventor 周黎琴楼大勇胡斐赵金凯张宏宇
Owner 诸暨市人民医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap